ClinicalTrials.gg
RecruitingNCT06305234Updated Mar 24, 2026

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

An observational study in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Recruiting at 11 sites in United States. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by BioMarin Pharmaceutical · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Phenylketonurias by BioMarin Pharmaceutical — 3 open to participants now, 5 under way, 1 of them phase 3. Phenylketonurias · BioMarin Pharmaceutical.

Started
2024
the only one that year
Observational
8 of 35
2 open now
Registered
33rd of 35
by date

Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the only one that started in 2024, is one of 8 observational ones, and was the 33rd registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

3 of the 35 studies in Phenylketonurias by BioMarin Pharmaceutical are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Phenylketonurias by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503.

Read the detailed description

This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503. Subjects participating in the 165-501 study who consent to participate in this study (165-503) will be requested to provide pre-dose blood samples for Phe, immunologic and inflammatory marker testing approximately every 3 months for the first 3 years of participation, then every 6 months for the remainder of the study. Subjects will be requested to provide additional pre-dose blood samples at the time of Study 165-501 -protocol defined safety events. Additional pre-dose samples will be drawn as per standard of care as detailed in protocol 165-501. The blood Phe, immunologic (PAL IgG, PEG IgG, PEG IgM, anti-pegvaliase IgE), and inflammatory (C3/C4, hsCRP) markers, will be sent to a central laboratory for processing. Data collected in the 165-501 study will be combined with the data collected in this study to decrease burden on sites for data entry and to avoid duplication of ADR reporting (see Criteria for Evaluation). The combined data will be reported in the Clinical Study Report for this study. Subjects can withdraw from Study 165-503 and remain on Study 165-501, but they cannot withdraw from Study 165-501 and remain on Study 165-503 as safety events and other data-points are collected in Study 165-501.

03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • PKU
  • Phenylketonuria
  • Palynziq
  • pegvaliase
  • observational
  • safety study
  • immunogenicity assessment
  • inflammatory assessment
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects enrolled at US sites participating in the 165-501 study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects enrolled at US sites participating in the 165-501 study.

Exclusion criteria

Exclusion Criteria:

  • Legal incapacity or limited legal capacity without legal guardian representation.
  • Subject is unable or unwilling to provide for the additional interventional burden of the study (blood sampling).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation

06

What researchers measure

Primary outcomes

  1. To evaluate immunologic and inflammatory responses associated with occurrences of

    * Acute systemic hypersensitivity reaction * Anaphylaxis * Angioedema * Serum sickness * Severe hypersensitivity reaction * Severe or Persistent arthralgia * Severe injection site reaction

    Time frame: A maximum of 10 years treatment duration.

Secondary outcomes

  1. Evaluation of immunologic and/or inflammatory responses over time

    To evaluate immunologic and inflammatory responses (immunologic testing, inflammatory markers) associated with occurrences of end-organ function (eg, kidney, liver) related, immune-mediated adverse drug reactions (ADRs)\*

    Time frame: A maximum of 10 years treatment duration.

  2. Evaluation of immunologic responses over time

    To evaluate the potential association between immunologic responses and blood Phe levels \* A list of end-organ function related, immune-mediated ADRs is included as an appendix to the statistical analysis plan (SAP).

    Time frame: A maximum of 10 years treatment duration.

07

Study locations

11 of 11 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2033, 117 months after the start.

Of 22 observational studies under Phenylketonurias, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 117 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Mar 12, 2024
StartActual
Jan 20, 2024
Primary completionEst.
Nov 18, 2033
CompletionEst.
Nov 18, 2033
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06305234
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Jan 20, 2024
Primary completion
Nov 18, 2033 (estimated)
Completion
Nov 18, 2033 (estimated)
Last update
Mar 24, 2026

Study contacts

165-503 Program Director
Contact
medinfo@bmrn.com
1-800-983-4587
Medical Director, MD
Contact
medinfo@bmrn.com
1-800-983-4587
Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion